INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic infl ammatory disease that causes signifi cant morbidity and mortality. The combined use of biological agents targeting tumour necrosis factor (TNF) and methotrexate (MTX) has produced signifi cant improvements in clinical, radiographic and functional outcomes that were not previously seen and has revolutionised the treatment goal of RA to clinical remission, structural remission and functional remission. [1] [2] [3] [4] [5] The next goal should be remission without the use of biological agents and subsequent drug-free remission. Although global evidence of the effi cacy and safety of TNF inhibitors such as infl iximab has accumulated, including the ATTRACT study, ASPIRE study, our RECONFIRM Discontinuation of infl iximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study studies and many others, [5] [6] [7] [8] [9] [10] there is no well-established fi rm evidence for remission free from the use of biological agents.
The initial report of the potential for remission without the use of biological agents in patients with RA was reported by a British group (TNF20 study). 11 The combination of infl iximab and MTX in patients with early RA who had fewer than 12 months of symptoms provided tight control of the disease activity and a signifi cant reduction in MRI evidence of synovitis and erosions at 1 year. At 2 years, functional and quality of life benefi ts were sustained, despite withdrawal of infl iximab treatment. On the other hand, the Behandelstrategieën (BeSt) study was conducted to observe clinical and radiological outcomes of patients with early RA treated with initial infliximab and MTX who discontinued infl iximab after achieving a sustained Disease Activity Score (DAS) ≤2. 4 . Five years after receiving infl iximab and MTX as initial treatment for RA, 58% of 120 patients discontinued infl iximab because of a continuous DAS ≤2. 4 and 19% of patients have stopped all antirheumatic drugs and remain in clinical remission, with minimal joint damage progression. These fi ndings indicate that treatment using infl iximab and MTX, guided by DAS, is an effective and tight control to maintain low disease activity (LDA) and may alter the course of early RA. [12] [13] [14] [15] [16] Discontinuation of TNF inhibitors after acquisition of LDA is important for reasons of safety and economy. For instance, the problem of the incidence of haematological malignancy owing to the longterm use of TNF inhibitors remains unresolved. In Japan a large majority of patients have to pay 30% of their medical costs and all wish to know for how long biological agents must be continued, but we have no answer. We successfully discontinued infl iximab after attaining DAS-guided remission for >24 weeks, 10 but evidence based on multicentre studies is needed. Reports published to date on this topic are confi ned to those from the BeSt study and TNF20 study involving only patients at an early stage of RA. [11] [12] [13] [14] [15] [16] Thus, this multicentre study was undertaken to seek the possibility of discontinuing infl iximab after attaining DAS-guided remission and maintaining LDA without infl iximab, in patients with RA, including patients with long-established disease, and to evaluate progression of articular destruction and functional disabilities during the discontinuation.
PATIENTS AND METHODS Patients
Data and information on patients with RA fulfi lling the diagnostic criteria of the American College of Rheumatology were collected from 26 centres of remission induction by Remicade in RA (RRR) investigator groups in Japan. 17 Disease activity of individual patients was assessed by Disease Activity Score, including a 28-joint count (DAS28)-erythrocyte sedimentation rate (ESR) or DAS28-C reactive protein (CRP) that was calculated according to the authorised formula (http://www.das-score.nl/, accessed 15 February 2010). 18 Since none of the patients, except for one, achieved LDA measured by DAS28 despite MTX or a combination of MTX and other disease-modifying antirheumatic drugs for at least 3 months, infl iximab treatment (3 mg kg, every 8 weeks) was administered in the investigators' institutions, according to the treatment guideline proposed by the Japan College of Rheumatology. 17 Joint damage was assessed by the van der Heijde-modifi ed total Sharp score (mTSS) 19 and for 102 patients, x-ray images of the hands and feet at baseline, RRR-study entry and 1 year after the study were available; these were evaluable for 49 patients owing to loss of the radiographs and/or low quality of the x-ray images. 20 21 Two blinded expert readers independently scored articular damage and progression according to the mTSS scoring method. The difference between the two readers' scores for each patient's radiographs was <1% of the maximum mTSS score-that is, 448. 9 20 21 To confi rm that the x-ray results of the 49 patients represented the outcomes of the whole group, we compared multiple background characteristics and changes of each characteristic from baseline to RRRstudy entry between 49 patients with evaluable x-ray images and 53 patients without them and no signifi cant difference was seen between the two groups.
After patients had achieved DAS28 (ESR)<3.2 (LDA) for >24 weeks, informed consent to discontinue infl iximab was obtained from 126 patients. Other criteria were that patients were controlled with <5 mg/day of oral prednisolone (PSL) and were >18 years old. Concomitant use of MTX was started in all patients, and the dose of MTX was determined by each attending doctor. Twelve patients dropped out at the screening period, and 114 patients were enrolled in the study and discontinued infl iximab (fi gure 1). The demographic indicators and baseline disease characteristics of the 114 patients enrolled are summarised in table 1.
Procedures
Study protocol was a simple observation after discontinuation of infl iximab. The follow-up observation was monitored by symptoms, signs and DAS28 (ESR) every 4-13 weeks for 2 years. The dose of concomitant MTX was basically consistent, but tapering of non-steroidal anti-infl ammatory drugs and glucocorticoid was allowed during the study period. The primary end points were that after discontinuing infl iximab, DAS28 remains <3.2 (LDA) for 1 year and (B) yearly progression of mTSS remains <0.5 (structural remission) for 1 year. Secondary end points were DAS28 remains <2.6 (clinical remission) for 1 year, DAS28 remains <3.2 for 2 years, yearly progression of mTSS remains <0.5 for 2 years and no rescue with infl iximab for 1 or 2 years is needed, after discontinuing infl iximab. When a fl are-up occurred in patients after the discontinuation, restart of infl iximab was allowed and patients were categorised into the 'RRR-failed' group. For the restart of infl iximab, the same dose (3 mg/kg) and the same premedication as used before the study entry were used.
Statistical analysis
Baseline characteristics of patients are summarised in table 1 using the mean values for continuous variables. All multivariate analyses were conducted using the variables gender, age, duration of disease, DAS28 (ESR) score, DAS28 (CRP) score, tender joint count (0-28), swollen joint count (0-28), patient global assessment of disease activity (PaGA, 0-100 mm, visual analogue scale), ESR, CRP, Health Assessment Questionnaire-Disability Index (HAQ-DI), rheumatoid factor (RF), MTX dose and PSL dose at baseline. Spearman correlation analyses were performed to evaluate the association between multivariables at RRR-study entry and DAS28 at the primary end point (last observation carried forward) of 102 patients. Logistic regression analysis was carried out to estimate DAS28 at the primary end point as dependent variables (probability) by DAS28 at RRR entry as independent variables. A receiver operating characteristic (ROC) curve was developed based on the logistic analysis and the signifi cant cut-off point was determined from the curve. For categorical response parameters, group comparisons were made using a non-parametric Wilcoxon t test. Statistical analyses were performed using JMP software version 7 (SAS Institute, Cary, North Carolina, USA). All reported p values are two sided and p values <0.05 were considered signifi cant.
RESULTS

Study end points
The demographic indicators and baseline characteristics of the 114 patients enrolled were as follows: mean age 51.4 years, mean disease duration 5.9 years and mean mTSS 63.3, indicating that the population included patients with long-established disease, and the mean DAS28 (ESR) score was 5.5, implying that most patients had highly active disease (table 1) . Figure 1 shows the study profi le. After maintaining DAS28<3.2 (LDA) for >24 weeks by infl iximab treatment, infl iximab was discontinued in 114 patients. Twelve patients withdrew because they moved from area (n=2) and for other reasons (n=10), and thus DAS28 could be evaluated in 102 patients at year 1.
Of the 102 patients, 56 patients achieved the primary end point having a DAS28<3.2 and remaining without infl iximab for 1 year after the discontinuation (fi gure 2A). Thus, 55% of the enrolled patients met the primary end point that LDA was maintained for 1 year after discontinuing infl iximab. Furthermore, 44 patients (43%) reached DAS<2.6 after the discontinuation. On the other hand, 29 patients fl ared within 1 year (mean duration was 6.4 months) after the discontinuation and in 17 patients DAS28 was >3.2 at year 1 and thus RRR failed for 46 patients (45%) at year 1. Re-treatment with infl iximab in 32 patients was effective and the majority of patients reached DAS28<3.2 within 24 weeks (fi gure 2B). Minimal adverse reactions at infusion of the agent were seen in fi ve patients only at the fi rst or second infusion.
To clarify the background factors related to the RRRachievement, multiple clinical parameters at baseline were compared between patients for whom RRR was achieved and those for whom it failed. Patients for whom RRR was achieved were younger (49.5 vs 56.1), their disease duration was shorter (4.8 vs 7.8) and mTSS was lower (46.9 vs 97.2) than for those for whom RRR failed. Among 56 patients who achieved RRR, 10 patients had early RA (disease duration <1.0 year) and eight long-established disease (>10 years). Of 46 patients for whom RRR failed, eight had early RA and 12 established disease. These results imply that infl iximab can be discontinued in patients with long-established RA. In contrast, no signifi cant difference was seen in gender, DAS including DAS28, tender or swollen joint count, ESR and CRP, HAQ-DI, RF and the dose of MTX and PSL. Since these factors interact with one another, we analysed the relationship between RRR-achievement and a series of clinical parameters at baseline using multivariate analysis after adjusting for confounding variables. No signifi cant relations Figure 2 Changes of Disease Activity Score, including a 28-joint count (DAS28) in patients with remission induction by Remicade in rheumatoid arthritis-achieved (RRR-achieved) and patients for whom RRR failed (RRR-failed). (A) Changes of Disease Activity Score, including a 28-joint count (DAS28) at baseline when infl iximab (IFX) was administered, at RRR-study entry when infl iximab was discontinued and at the primary end point at week 52 after discontinuing IFX in 56 patients who were still satisfi ed with DAS28 (erythrocyte sedimentation rate (ESR)) <3.2 at week 52, RRRachieved'. (B) Changes of DAS28 at baseline, at RRR entry and the end point in 46 patients whose disease activity fl ared after the discontinuation of IFX or DAS28 >3.2 at week 52, 'RRR-failed'. The lower right panel shows changes of DAS28 after the restarting IFX in 32 patients for whom RRR failed. between RRR-achievement and age, gender, DAS28 (ESR) score, PaGA and CRP were found, whereas a signifi cant correlation was found with disease duration (p=0.0019) and serum levels of RF (p=0.0128) in RRR-achievement.
DAS28-ESR
To determine the correlation of DAS28 at the primary end point with clinical parameters at RRR-study entry, univariate analysis of multiple variables was carried out. No signifi cant correlations between DAS28 (ESR) at the primary end point and a series of clinical parameters were found, whereas DAS28 (ESR) and DAS28 (CRP) at RRR-entry were signifi cantly correlated with DAS28 (ESR) at the primary end point. Subsequently, logistic regression analysis to estimate the probability of DAS28<3.2 at the primary end point as dependent variable by DAS28 at RRR-entry as independent variable was assessed. A signifi cant logistic regression curve was drawn between the dependent and independent variables (p=0.0005) (fi gure 3A). Thus, DAS28 at RRR-study entry had the most marked correlation with the maintenance of LDA for 1 year after the discontinuation. By reciprocal statistics, DAS28 at RRR-study entry was estimated as 2.22, to attain DAS28<3.2 at the end point in 50% of the 102 patients (fi gure 3A). Furthermore, 71.4% of patients whose DAS28 at study entry was <2.225, a cut-off point calculated from the ROC curve, continued to have DAS28<3.2 for 1 year, whereas only 32.6% of patients whose DAS28 at RRR-entry was 2.225-3.2 continued to have DAS28<3.2 (fi gure 3B), indicating that 'deep remission' was required to maintain lower disease activity for 1 year after discontinuation of infl iximab.
Structural and functional changes
From the 102 patients enrolled in the study, 49 patients were selected in whom both hand and feet x-ray data were available and evaluable; experts examined the structural damage before and after the infl iximab treatment. When the baseline characteristics of the 49 patients in the study were compared with the rest of the patients in the study with insuffi cient x-ray data (n=53), no signifi cant difference was seen. Next, the baseline characteristics of the 33 patients who achieved RRR and 16 patients for whom RRR failed were compared. As described in table 1, disease duration was shorter and mTSS was lower in patients who achieved RRR than in patients for whom RRR failed, but yearly progression of mTSS (∆mTSS) was comparable between two groups (table 2). ∆mTSS at RRR entry was also comparable between two groups. However, means (0.3 vs 1.6) and medians (0.0 vs 1.5) of ∆mTSS were lower in the RRRachieved group than in the RRR-failed group and more patients in the RRR-achieved group (67%) achieved ∆mTSS<0.5, radiographic remission, than patients in the RRR-failed group (44%). Thus, another primary end point for structural remission was achieved for 1 year after the discontinuation. Furthermore, HAQ-DI at baseline and RRR entry was comparable between patients for whom RRR was achieved and those for whom it failed, whereas HAQ-DI at the primary end point in patients who achieved RRR was signifi cantly lower than that in patients for whom RRR failed (0.174 vs 0.614) (fi gure 4).
DISCUSSION
This multicentre study was undertaken to determine the possibility of discontinuing infl iximab treatment in patients with RA after acquiring DAS-guided LDA, including those with longestablished disease. Among 102 patients who could be evaluated at year 1, 56 patients (55%) satisfi ed the primary end point by maintaining DAS28<3.2 (LDA) and 44 patients (43%) reached DAS<2.6 (remission), remaining without infl iximab at year 1 after the discontinuation. Of the 102 patients, 83 (81.4%) were in clinical remission at study entry and after discontinuing infl iximab, 39/83 patients (47%) remained in remission and 10/83 patients (12%) progressed to LDA at the primary end point.
These data are similar to those of the BeSt study. However, the greatest difference between the patient populations enrolled in the two studies is mean disease duration-0.4 years in the BeSt study versus 5.9 years in our RRR study. [12] [13] [14] [15] [16] Joint destruction also differed between the two studies-mean mTSS 7.0 in the BeSt study versus 63.3 in our RRR study-suggesting that discontinuation of infl iximab after reaching LDA is possible in patients with early RA and also in patients with long-established disease. [13] [14] [15] On the other hand, among multiple clinical parameters at baseline, disease duration was statistically related to RRR-achievement by multivariate analysis and disease duration was shorter (4.8 vs 7.8) and mTSS was lower (46.9 vs 97.2) in patients who achieved Figure 3 Logistic analysis of probability of Disease Activity Score, including a 28-joint count (DAS28) was <3.2 at primary end point by DAS28 at remission induction by Remicade in rheumatoid arthritis entry (RRR entry). (A) Logistic regression analysis to estimate DAS28 at primary end point as dependent variables by DAS28 at RRR entry as independent variables. The y-axis shows the probability of DAS28 <3.2 at the primary end point after the 52 weeks discontinuation of infl iximab and a scatter diagram of an individual patient and logistic regression curve (solid line) are shown. To attain DAS28 <3.2 at the end point in 50% of the 102 patients, DAS28 at RRR study entry was estimated by reciprocal statistics. (B) From the receiver operating characteristic curve based on the logistic regression analysis above, the cut-off point of DAS28 at RRR-study entry was 2.225. Subsequently, one-way analysis of DAS28 at the primary end point by DAS28 at study entry, <2.225 versus between 2.225 and 3.2, was performed and the statistical difference of the two groups was sought by non-parametric Wilcoxon t test (***p<0.001). ESR, erythrocyte sedimentation rate. RRR than in those for whom RRR failed. These results imply that remission free from biological agents can be more easily obtained in patients with shorter disease duration than in those with more established disease, but discontinuation of infl iximab is still possible even in patients with long-established RA, because eight patients whose disease duration was >10 years successfully remained without infl iximab for 1 year. Among 102 evaluated patients, disease in 29 patients fl ared within 1 year, 17 patients had DAS28>3.2 at year 1 after discontinuing infl iximab and 32 patients had already been re-treated with infl iximab. One of the major concerns of restarting infliximab is the possibility of an infusion reaction after the longterm discontinuation, partly owing to human anti-chimeric antibodies. 22 However, minimal adverse reactions at infusion of the agent were seen only in fi ve patients at the fi rst or second infusion. Another concern is the progress of joint damage after discontinuation of infl iximab. However, although the yearly progression of mTSS at RRR-study entry was also comparable between two groups, means (0.3 vs 1.6) and medians (0.0 vs 1.5) of ∆mTSS were shorter in the RRR-achieved group than in the RRR-failed group. Furthermore, at year 1 after the discontinuation of infl iximab, more patients in the RRR-achieved group (67%) tended to satisfy ∆mTSS<0.5-that is, structural remission, than those in the RRR-failed group (44%) and HAQ-DI in patients who achieved RRR was signifi cantly lower than that in patients for whom RRR failed (0.174 vs 0.614). These results indicate that both structural remission and functional remission were maintained for 1 year in patients with LDA even after discontinuing infl iximab.
This study also shows the signifi cance of DAS-guided tight control of RA in order to maintain remission free from biological agents. There was a signifi cant correlation between DAS28 (ESR) or DAS28 (CRP) at RRR entry and DAS28 (ESR) at year 1 after the discontinuation of infl iximab by univariate analysis of multiple variables and a logistic regression analysis. Thus, DAS28 at RRR-study entry had the greatest correlation with maintenance of LDA for 1 year after discontinuation. Also, DAS28 at study entry was mainly infl uenced by PaGA and ESR among the composite measures. By reciprocal statistics, the estimated DAS28 (ESR) at RRR-study entry was 2.22 (1.85-2.70), to attain DAS28<3.2 at the primary end point in 50% of the 102 patients studied. Also, 71.4% of patients whose DAS28 at study entry was <2.225, a cut-off point calculated from ROC curve, remained DAS28<3.2 for 1 year, whereas only 32.6% of patients whose DAS28 at RRR-entry was 2.225-3.2 remained DAS28<3.2. These results indicate that 'deep remission' appears to be required to maintain lower disease activity for 1 year after discontinuation of infl iximab. About 55% of the 102 patients, who were in an LDA state for >24 weeks with infl iximab and MTX treatment, could discontinue infl iximab for >1 year without progression of radiological articular destruction or functional disturbance. These data may have signifi cant implications for the optimal use of expensive biological treatments: (a) re-treatment with infl iximab is efficient and tolerable in the patients for whom RRR failed; (b) DASguided monitoring is valuable to keep tight control; (c) 'deep remission' by tight control is required to maintain discontinuation of infl iximab; (d) remission free from biological agents may be easier to attain in patients with early RA, but is possible for patients with long-established disease; (e) treatment aimed at reaching a target of LDA is pivotal to the approach to remission free from biological agents. Finally, TNFα is not a cause of RA, but if appropriate treatment with infl iximab can lead to drug-free remission, TNF inhibitors may shut down pathological processes and may change or modify the disease course in RA. Thus, a clinical and basic research approach to the 'processdriven disease' of RA is warranted.
